NeuroSense Investor Relations

NASDAQNRSN

Investor Relations

About Us

Pipeline

Media

Investor RelationsClick here to open mobile navigation

Recent News

Investor Alerts

Jun 11, 2026

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALS Expands intellectual property protection in one of the world's leading pharmaceutical markets, following...

Jun 9, 2026

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil patents CAMBRIDGE, Mass., June 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"...

Apr 28, 2026

NeuroSense Announces Pricing of Insider-Led PIPE Financing

Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics...

Latest Events

No events to display

Investor Presentation

Download PDF

Board Diversity Matrix

Download PDF

Investor Relations

Home

Research

About

Publications